Proteostasis Therapeutics Inc. (Nasdaq: PTI) to Ring the Nasdaq Stock Market Opening Bell in Celebration of IPO
February 11 2016 - 8:24AM
What: Proteostasis Therapeutics, Inc.
(Nasdaq:PTI), a company developing novel therapeutics that regulate
protein biosynthesis, folding, trafficking and clearance to improve
outcomes for patients with protein processing diseases, will visit
the Nasdaq MarketSite in Times Square to celebrate its initial
public offering (IPO).
In honor of the occasion, Meenu Chhabra, President and
Chief Executive Officer, will ring the Opening
Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Thursday, February 11, 2016 – 9:15 a.m. to
9:30 a.m. ET
Proteostasis Therapeutics Media Contact:Dan
BudwickPure Communications(973)
271-6085dan@purecommunicationsinc.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies please visit our Facebook page
at:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page:http://instagram.com/nasdaq
For news tweets, please visit our Twitter page
at:http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page:http://nasdaq.tumblr.com/
Webcast: A webcast of the Nasdaq Opening Bell
will be available at: https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on
the market open of your choice.
About Proteostasis
TherapeuticsProteostasis Therapeutics, Inc. (PTI) is
developing disease-modifying therapeutics for diseases of protein
processing. Using the DRT™ platform, a phenotypic screening
approach based on the use of functionally pertinent cellular assays
and disease relevant models, PTI identifies highly selective drug
candidates that modulate the proteostasis imbalance in the cell. In
addition to its multiple wholly-owned programs in cystic fibrosis,
PTI has formed collaborations with Biogen New Ventures Inc. to
research and identify therapeutic candidates for neurodegenerative
disease and with Astellas Pharma Inc. to research and identify
therapies targeting the Unfolded Protein Response (UPR) pathway.
For more information visit www.proteostasis.com.
About NasdaqNasdaq (Nasdaq:NDAQ)
is a leading provider of trading, clearing, exchange technology,
listing, information and public company services across six
continents. Through its diverse portfolio of solutions, Nasdaq
enables customers to plan, optimize and execute their business
vision with confidence, using proven technologies that provide
transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock
market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,700 listed companies with a market
value of approximately $9.6 trillion and nearly 10,000 corporate
clients. To learn more, visit: nasdaq.com/ambition or
business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024